Group 1 - The core viewpoint of the article highlights that Yaoshi Bang (09885) has seen a nearly 6% increase in stock price, attributed to its inclusion in the MSCI China Small Cap Index and a positive earnings forecast [1][1][1] - The company expects its profit attributable to shareholders for the half-year ending June 30, 2025, to be no less than RMB 70 million, which is more than three times the RMB 21.8 million profit expected for the half-year ending June 30, 2024 [1][1][1] - Longcheng Securities identifies Yaoshi Bang as a leader in the digital ecosystem construction of the domestic off-hospital pharmaceutical industry, noting steady growth in both its platform and self-operated businesses [1][1][1] Group 2 - The company is undergoing a strategic upgrade from "scale expansion" to "profit enhancement," with its proprietary brand business showing high growth [1][1][1] - For the period from January to April 2025, the company's GMV for its proprietary brand business reached RMB 717 million, representing a year-on-year growth of 108.1% [1][1][1] - The GMV for the company's proprietary brand business alone reached RMB 560 million, with a remarkable year-on-year growth of 532.3% [1][1][1]
港股异动 | 药师帮(09885)涨近6% 公司获纳入MSCI全球小型股指数 自有品牌业务规模呈高增长态势